TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18198804
Drug: Standard interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard interventions (mask optimization, heated humidification, topical nasal therapy, sleep apnea education)
Study: 16310576
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (30 grams daily for 12 weeks)
Study: 9829029
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy (BT) plus fluvoxamine (maximum dosage 300 mg, mean dose 288.1 mg)
Study: 9829029
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy (BT) plus placebo
Study: 31285228
Drug: Filociclovir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filociclovir (100 mg, 350 mg, or 750 mg daily for 7 days)
Study: 31285228
Drug: Filociclovir (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filociclovir (750 mg)
Study: 31285228
Drug: Filociclovir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filociclovir (100 mg, 350 mg, or 750 mg)
Study: 31285228
Drug: Filociclovir (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filociclovir (350 mg)
Study: 28138867
Drug: Relational active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relational active music therapy treatments
Study: 28138867
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (physiotherapy and occupational therapy) + Relational active music therapy
Study: 26497495
Drug: Total neoadjuvant
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total neoadjuvant therapy (TNT) with FOLFOX/CAPEOX before induction neoadjuvant chemotherapy (INCT) or after consolidation neoadjuvant chemotherapy (CNCT), with 5‐FU or capecitabine‐based chemoradiation.
Study: 21536947
Drug: midazolam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam (0.3 mg/kg; max 15 mg)
Study: 17721103
Drug: Drug conservation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug conservation arm (CD4 T-cell-guided ART strategy)
Study: 14562945
Drug: Three 20
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 20 mg intramuscular injections of a preS2/S vaccine (GenHevac‐B) on days 0, 30 and 60
Study: 14562945
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vaccine therapy)
Study: 8684200
Drug: Fresh-frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh-frozen plasma (FFP) 20 mL/kg followed by 10 mL/kg after 24 h
Study: 8684200
Drug: Gelatin-based plasma
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin-based plasma substitute 20 mL/kg followed by 10 mL/kg after 24 h
Study: 8684200
Drug: Glucose (control)
Normalized name: GLUCOSE CONTROL
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose (control) 20 mL/kg followed by 10 mL/kg after 24 h
Study: 6760980
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg nocte)
Study: 6760980
Drug: Pizotifen (2-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen (2-3 mg per day in three administrations)
Study: 29528499
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1200 mg daily
Study: 29528499
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1600 mg daily
Study: 27464860
Drug: Oxycodone 140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 140 μg/kg (Group O/70)
Study: 27464860
Drug: Oxycodone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 200 μg/kg (Group O/100)
Study: 23431348
Drug: Xiaoqinglong granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoqinglong granules (XQLG) as add-on therapy to seretide
Study: 18633426
Drug: Irbesartan high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan high-dose combination therapy
Study: 16385103
Drug: Methodologic features
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methodologic features (slow titration, flexible dosing, minimizing concomitant analgesics, fewer study sites)
Study: 9890409
Drug: Amrinone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (1.5 mg/kg bolus in 30 min and then 10 microg/kg/min for 1 h 30 min)
Study: 2015727
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil (120 mg) and propranolol (80 mg) combination
Study: 2015727
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil (120 mg) and metoprolol (100 mg) combination
Study: 2015727
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil (120 mg) and pindolol (5 mg) combination
Study: 2015727
Drug: Beta-blockers (propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (propranolol, metoprolol, pindolol) alone
Study: 2015727
Drug: Verapamil and
Normalized name: trandolapril and verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil and beta-blocker combinations
Study: 2015727
Drug: All verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: All verapamil and beta-blocker combinations
Study: 19732888
Drug: Combined metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined metformin and clomiphene citrate
Study: 31553833
Drug: Intravenous ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous ustekinumab 130 mg
Study: 31553833
Drug: Intravenous ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous ustekinumab 6 mg/kg
Study: 31553833
Drug: Subcutaneous ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous ustekinumab 90 mg every 12 weeks
Study: 31553833
Drug: Subcutaneous ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous ustekinumab 90 mg every 8 weeks
Study: 19470045
Drug: Water-soluble nail
Normalized name: Fungi-Nail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-soluble nail lacquer applied once daily on the affected fingernails of the left hand for 24 consecutive weeks
Study: 12851662
Drug: 21 mg/day
Normalized name: nicotine 21 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg/day transdermal nicotine system
Study: 8956390
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ketamine plus 0.5 mg morphine
Study: 8956390
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group A (10 mL saline with no additive)
Study: 1574977
Drug: Propofol (induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (induced with propofol and maintained with an infusion of propofol 12 mg/kg/h for the first 15 min, followed by 8 mg/kg/h)
Study: 2932989
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 1 mg
Study: 25864998
Drug: Intramedullary nailing
Normalized name: FUNGI NAIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramedullary nailing and antirotator proximal femoral nail implant (TST, Turkey)
Study: 9890197
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (sFas > or =2.06 ng/ml)
Study: 9890197
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (sFas <2.06 ng/ml)
Study: 2672998
Drug: buzepide metiodide
Normalized name: buzepide metiodide
Approvals — FDA: no, EMA: no, PMDA: no
Description: buzepide metiodide and haloperidol combination
Study: 31307913
Drug: Genistein supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein supplementation (2 capsules daily for 12 weeks, each containing 54 mg genistein)
Study: 31307913
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules daily for 12 weeks)
Study: 25643928
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (continuation of previous treatments such as moisturization, packing, and cautery)
Study: 16734394
Drug: Isoflavone intake
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone intake (75 mg of isoflavone conjugates/day)
Study: 16734394
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of isoflavone plus walking
Study: 12658208
Drug: Inhaled epoprostenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled epoprostenol (60 microg)
Study: 10573618
Drug: Preoperative subcutaneous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative subcutaneous heparin (Group B, 8 patients - 4 laparoscopic and 4 open)
Study: 8706070
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers and diuretics
Study: 1831397
Drug: High-dose medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medroxyprogesterone acetate (MPA) 1000 mg i.m. daily for 15 days, followed by 1000 mg weekly
Study: 1831397
Drug: Estramustine 280
Normalized name: estramustine 280 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estramustine 280 mg per os twice daily
Study: 6918402
Drug: Mevinolin 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevinolin 6.25 mg twice daily for 4 weeks
Study: 6918402
Drug: Mevinolin 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevinolin 12.5 mg twice daily for 4 weeks
Study: 6918402
Drug: Mevinolin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevinolin 25 mg twice daily for 4 weeks
Study: 6918402
Drug: Mevinolin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevinolin 50 mg twice daily for 4 weeks
Study: 6918402
Drug: Mevinolin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevinolin (all doses)
Study: 3893605
Drug: Regular medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular medication (Control)
Study: 20398378
Drug: Pre-operative fluid
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative fluid therapy
Study: 16003036
Drug: Eccentric training
Normalized name: SYRINGE 60ML ECCENTRIC TIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eccentric training (squats on a 25 degrees decline board, 3 x 15 repetitions twice daily for 12 weeks)
Study: 8909736
Drug: diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac sodium 100 mg (preoperative administration)
Study: 8909736
Drug: diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac sodium 100 mg (postoperative administration)
Study: 8909736
Drug: diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac sodium 100 mg (both pre- and postoperative)
Study: 1869646
Drug: Topical masoprocol
Normalized name: masoprocol Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical masoprocol applied twice a day for 14 to 28 days
Study: 1869646
Drug: Topical masoprocol
Normalized name: masoprocol Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical masoprocol
Study: 6213376
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg MPA with 250 mg testosterone enanthate (TE) monthly injection
Study: 30700274
Drug: HPV vaccination
Normalized name: HPV-16 trojan peptide vaccine
DrugBank: HPV-16 trojan peptide vaccine (DB17496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccination (at least one dose)
Study: 29473223
Drug: Subcrestal placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcrestal placement of implants
Study: 29473223
Drug: Epicrestal placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epicrestal placement of implants
Study: 23044236
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day ETV (group A)
Study: 23044236
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day ETV maleate (group B)
Study: 15983801
Drug: 50 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ng/ml ketamine
Study: 15983801
Drug: Ketamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (50 ng/ml or 100 ng/ml)
Study: 1678941
Drug: Repetitive injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive injections of vecuronium (Group 1)
Study: 6343664
Drug: Cefotetan (CTT)
Normalized name: Cefotetan
DrugBank: Cefotetan (DB01330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotetan (CTT) 2g daily
Study: 6343664
Drug: Cefmetazole (CMZ)
Normalized name: Cefmetazole
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefmetazole (CMZ) 4g daily
Study: 29962090
Drug: Web-based acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based acceptance and commitment therapy (ACT) program (YOLO), 4 weeks
Study: 27255908
Drug: Functional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional physical therapy program conducted over-ground (fPT)
Study: 27255908
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy only
Study: 17660490
Drug: VTE during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTE during chemotherapy
Study: 16278629
Drug: Sequential combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combined spinal-epidural (CSE) anesthesia
Study: 11861034
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT) with conjugated estrogens 0.625 mg/day for 4 weeks
Study: 11861034
Drug: Thrombin-stimulated platelets
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin-stimulated platelets (0.1 U/ml)
Study: 11861034
Drug: Thrombin-stimulated platelets
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin-stimulated platelets (0.3 U/ml)
Study: 10455479
Drug: Bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5 mg once daily)
Study: 10455479
Drug: Bendrofluazide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (2.5 mg once daily)
Study: 2611092
Drug: Intranasal lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal lignocaine (100 mg dose)
Study: 2611092
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine (100 mg dose)
Study: 31245885
Drug: Antibiotic prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylactic group (2 g of cefotiam during endoscopic injection)
Study: 31245885
Drug: On-demand group
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand group (no prophylactic antibiotics)
Study: 31245885
Drug: Antibiotic prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylactic group
Study: 26314289
Drug: Telephone-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based treatment
Study: 8874911
Drug: Neostigmine (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.07 mg/kg)
Study: 3246212
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg trimethoprim (TMP)
Study: 3246212
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg cinoxacin (CNO)
Study: 30900815
Drug: 1.8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/d DHA+EPA
Study: 30900815
Drug: 3.6 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g/d EPA+DHA
Study: 30900815
Drug: 4.2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2 g/d ALA
Study: 30900815
Drug: 7.2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.2 g/d ALA
Study: 29871266
Drug: SLIT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLIT + drug group (sublingual immunotherapy with Dermatophagoides farinae drops and symptomatic therapy)
Study: 29871266
Drug: Drug group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug group (mometasone furoate nasal spray and desloratadine tablets)
Study: 23598691
Drug: Zinc (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (50 mg per day for 4 months)
Study: 21854273
Drug: Buprenorphine tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine tapering schedule
Study: 18046666
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with ACEIs and ARBs
Study: 18046666
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with ACEIs or ARBs
Study: 14730412
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg deramciclane
Study: 11563590
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment and secondary prophylaxis during PBSCT
Study: 31122493
Drug: Co-careldopa (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-careldopa (125 mg after initial doses of 62.5 mg)
Study: 20003341
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care management (standard GP consultation, medication, advice and education)
Study: 11472461
Drug: Captopril (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (angiotensin converting enzyme inhibitor)
Study: 11472461
Drug: Atenolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta blocker)
Study: 9735735
Drug: Warm-Up Active
Normalized name: Camphor (Synthetic) 5 mg in 100 g TOPICAL CREAM [ALLG Essentials Warm-up Accelerator]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm-Up Active Wound Therapy
Study: 9270567
Drug: Ropinirole (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (n = 116) starting dose of 0.25 mg tid, titrated to at least 1.5 mg tid (maximum dose, 8 mg tid)
Study: 2930837
Drug: Daunorubicin (DNR)
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin (DNR) or 4‐(9‐acridinylamino)methanesulfan‐m‐anisidide (AMSA) in combination with arabinosylcytosine (Ara‐C) and 6‐thioguanine (TG)
Study: 861135
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg digoxin tablets (Lanoxin)
Study: 861135
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg digoxin in solution in soft gelatin capsules (Lanoxicaps)
Study: 861135
Drug: Lanoxicaps (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanoxicaps (0.2 mg)
Study: 25872532
Drug: Levothyroxine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (25 mcg once daily, increased as needed to maintain TSH between 0.4 to 2.5 mU/L)
Study: 23868627
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing Omega‐3, Policosanol, Resveratrol, L‐carnitine, Monascus purpureus, Coenzyme Q10, Vitamin B6 and Vitamin B12
Study: 15575341
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal with dual-wave insulin bolus delivery
Study: 15575341
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal with normal insulin bolus delivery
Study: 15575341
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal with normal insulin bolus delivery
Study: 9422856
Drug: Anistreplase treatment
Normalized name: Anistreplase
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anistreplase treatment
Study: 8236505
Drug: IL-2 plus
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 plus L-carnitine (1000 mg/day orally)
Study: 18327427
Drug: Clarithromycin 15
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 15 mg/kg/day, twice a day
Study: 18327427
Drug: Erythromycin 30-50
Normalized name: erythromycin 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 30-50 mg/kg/day, four times daily
Study: 16360994
Drug: IV NAC
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV NAC 300 mg
Study: 16360994
Drug: IV NAC
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV NAC 600 mg
Study: 8620338
Drug: Colestipol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol (20 g/d)
Study: 8620338
Drug: Colestipol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol (20 g/d) + Simvastatin (20 mg/d)
Study: 2015715
Drug: Intraoperative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative and postoperative intravenous urokinase
Study: 2015715
Drug: Long-term sodium
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term sodium warfarin therapy
Study: 7006581
Drug: Simultaneous timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Simultaneous timolol treatment with epinephrine
Study: 7006581
Drug: Timolol and
Normalized name: timolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol and epinephrine combined therapy
Study: 30614289
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg) plus Myoinositol (600 mg) three times a day
Study: 30614289
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg) three times a day